McNicoll Lewis & Vlak Starts Keryx Biopharmaceuticals (KERX) at Buy; Two Strong PhIII Candidates Offer a Compelling Risk/Reward Opportunity
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Price: $3.36 --0%
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 17
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 17
Join SI Premium – FREE
McNicoll Lewis & Vlak initiates coverage on Keryx Biopharmaceuticals (NASDAQ: KERX) with a Buy. PT $33.
MLV analyst says, "Keryx has two promising compounds in Phase III (PhIII) trials for three distinct indications: perifosine for metastatic colorectal cancer (mCRC) and multiple myeloma (MM) - both conducted under Special Protocol Assessments (SPA) and Fast Track review; and Zerenex™ (ferric citrate) for hyperphosphatemia...We expect several near-term catalysts, including: 1) positive PhIII data for perifosine in mCRC in 4Q:11, 2) NDA filing for perifosine
in mCRC in 1Q:12, and 3) NDA filing for Zerenex in hyperphosphatemia in 3Q:12. Keryx has also stated its intent to establish a co-promotion agreement for Zerenex."
For more ratings news on Keryx Biopharmaceuticals click here and for the rating history of Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.60 yesterday.
MLV analyst says, "Keryx has two promising compounds in Phase III (PhIII) trials for three distinct indications: perifosine for metastatic colorectal cancer (mCRC) and multiple myeloma (MM) - both conducted under Special Protocol Assessments (SPA) and Fast Track review; and Zerenex™ (ferric citrate) for hyperphosphatemia...We expect several near-term catalysts, including: 1) positive PhIII data for perifosine in mCRC in 4Q:11, 2) NDA filing for perifosine
in mCRC in 1Q:12, and 3) NDA filing for Zerenex in hyperphosphatemia in 3Q:12. Keryx has also stated its intent to establish a co-promotion agreement for Zerenex."
For more ratings news on Keryx Biopharmaceuticals click here and for the rating history of Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Starts Jet2 plc (JET2:LN) (DRTGF) at Buy
- BMO Capital Starts Semtech Corp. (SMTC) at Outperform
- BMO Capital Starts Broadcom Limited (AVGO) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
